Seems like the Seeking Alpha article turn what seemed to be a positive with Armistice/Steve Boyd letter to a negative with the pipeline being full of drugs that will never be commercially viable…. SA repeatedly states, this company or that company gave up on this drug in the pipeline, so it’s obviously not worth anything… I’m sure that’s what SA was saying about Fusilev and we all know there have been more than a few millions in revenue from that one. Oh and I bet that guy that said the Polio vaccine was worthless now might be reconsidering….. Raj and team are really good with their science; it’s their management that suffers. I bet Raj wishes he’s beefed up that patent when he acquired Fusilev!!! Hopefully he learns from his mistakes. It’s the management details Raj is bad with… not finding viable drugs… All this business about falling sales, the first quarter was hampered by some of the worst winter weather in decades or maybe ever!! So let’s not throw the baby out with the bath water. Have there been missteps yep, the Apaziquone trial is a disaster!! Blood in the study should have been anticipated and managed but instead of seeing the bad, I see that Raj felt this was a slam dunk and failed to dot the “I” and cross the “t”… Apaziquone will be a commercial drug at some point, we should have those revenues NOW!! Anyway…. I wonder how SA would stand up to a review of their work???
WIth the acknowledgement of Fusilev sales no longer being a driver, there is nothing really bad here for the shorts to hang there hats on!!! So maybe they will take their money and leave!
Sentiment: Strong Buy
You are dreaming!! CFO himself said they expect a significant drop in revenues. There was no statement about orphan drug exclusivity or fighting Sandoz in court for infringements. It's pretty apparent to me they hope annual revenues will stay somewhere north of $10M a quarter but SPPI is dead money until there are approvals of replacement revenues or a major player finds value in the pipeline. One last thing, Raj really dropped the ball on the Apaziquone trails, if they had thought it through they should have know they enzyme would affect results and why has it taken so long to get this resolved!! This is where he has really failed his shareholders!!!
Finally listened to the call, it's pretty apparent the Orphan Drug status will have little or no bearing on what Sandoz sells. AF was right!! Fusilev sales will be dropping like a rock and all who stated the effects of the court ruling would only affect 2% of sales are wrong!! I was stupid to believe you knew what you were talking about!!! I WONDER IF RAJ GETS HIS BONUS IN 2015!!!
As usual, Raj is clear as mud!
Whats to say I haven't... I actually have several hunderd call options and I was looking to push them out to January 2016 when I noticed there were none...
There are no call options available beyond November 2015!! It appears no one wants to write options past that point in time. I think it's a major sign the end is coming to the price suppression and the institutions don't want to miss the ride when this thing starts to move!! I haven't bought more shares in a while but I think it's time to prepare for greatness!!!
Man we are cooking with gas now!!
I honestly can't believe we are under $6, I don't buy the convertible debt speculation. This stock will burn the short interest at some point... But as long as Raj refuses to address the issues that hold the stock proce down we will continue to flounder. Raj is so smart when it comes to the medicine but so stupid when it comes to the business aspects. Shareholders want reassurance... A simple statement that Fusilev revenues are mostly protected until 2018 and if we get wind that our revenues are impacted by the generic, We'll sue them til their ears bleed!! Also since we have this huge sales force, lets pick a couple of the Sandoz generic products and work on adding them to our product list.. Lets take the fight to them. Ok, maybe that's not feasible but Raj needs to work on the business strategies. Pre-announce earnings, fund the buyback, make bonuses based on price per share... Where is Carl Icahn when you need him!! Anyway I have been in this for the long haul, I have 9 more years until retirement, so I remain patient.. I fully well expect my investment in SPPI to fund my beach house one day!!! He who laughs last, laughs loudest!!!
I just want Raj to be clear.. That's all.. There is to much uncertainity because Raj doesn't provide clear direction.
Maybe I'm thick but the data released to day should have pushed this up a buck and the only anchor here is the Fusilev uncertainity.
If Raj was instructed not to comment by legal... then say that!!! My point would be to voice that SPPI is going to fight the ruling... Make every effort to insure the orphan drug protection is maintained. Honestly I have no idea whether a hospital can order the generic and use it for what they want regardless of the protection. Clarifiy what we have.... How do you protect that?? What's the impact... Give me some numbers, best case worse case... What will they revenues been when generics hit the market... Obviously the dog an pony show didn't send the shorts heading for the hills. They see $105M in revenues going away.. Sooner than Later... They fact that we don't seem to have a plan is distrubing...
While I'm sure you are a knowledgeable fellow, but I'd rather heard it from Raj!! Address the elephant in the room and put it to bed...
Wow I sense frustration... you have been the voice of reason for a while!!! Apaziquone was the reason I originally invested in this company. I'm with you, it's time to provide clear direction!!
Raj is greedy or seems to be to me..We just need to get him to adopt a strategy that convinces Raj the best way for him to get rich is for us to get rich too!!!